Using ApoE2 to improve brain health in Alzheimer's patients
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
This study is looking at how a special protein called ApoE2 might help protect and treat people with Alzheimer's disease, especially those who are at higher risk because of their genes, by boosting brain health and slowing down the disease's progress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project ID | NIH-11225642 on NIH RePORTER |
What this research studies
This research aims to explore how introducing the human ApoE2 protein can help protect and treat patients with Alzheimer's disease, particularly those at high risk due to the ApoE4 genotype. The approach involves enhancing brain resilience by improving metabolism and synaptic activity, which could slow down the progression of Alzheimer's. Researchers have developed a method to produce a functional version of ApoE2 and a noninvasive way to deliver it to the brain, using innovative mouse models to test their hypotheses. The goal is to translate these findings into potential therapies for patients suffering from Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those who carry the ApoE4 allele.
Not a fit: Patients who do not have Alzheimer's disease or those with other forms of dementia unrelated to ApoE4 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly slow the progression of Alzheimer's disease and improve the quality of life for patients.
How similar studies have performed: While the approach of using ApoE2 for Alzheimer's treatment is innovative, similar strategies targeting neuroprotective mechanisms have shown promise in other studies.
Where this research is happening
Lawrence, United States
- University of Kansas Lawrence — Lawrence, United States (Active)
Researchers
- Principal investigator: Zhao, Liqin — University of Kansas Lawrence
- Study coordinator: Zhao, Liqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.